The table below summarizes the most recent Bausch Health Companies insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Bausch Health Companies insider buys are important for investors to follow.

Date	Insider	Price	Amount
11-30-2021 Insider Buy	Steven D. Miller Director	$24.23 CAGR »	$1,453,524.00 60,000 shares
8-5-2021 Insider Buy	Andrew C. Von Eschenbach Director	$25.94 CAGR »	$36,316.00 1,400 shares
8-4-2021 Insider Buy	Richard U. De Schutter Director	$25.01 CAGR »	$250,123.00 10,000 shares
6-5-2020 Insider Buy	ValueAct Holdings, L.P. Director	$19.24 CAGR »	$18,246,311.72 948,353 shares
3-12-2020 Insider Buy	Thomas W. Ross Sr. Director	$15.54 CAGR »	$38,837.50 2,500 shares
3-10-2020 Insider Buy	Richard U. De Schutter Director	$21.00 CAGR »	$184,792.36 8,800 shares
3-10-2020 Insider Buy	Andrew C. Von Eschenbach Director	$18.18 CAGR »	$19,996.35 1,100 shares
3-10-2020 Insider Buy	Christina Ackermann EVP AND GENERAL COUNSEL	$18.25 CAGR »	$80,105.65 4,390 shares
9-13-2019 Insider Buy	Joseph C. Papa CHAIRMAN & CEO	$23.31 CAGR »	$699,300.00 30,000 shares
8-16-2019 Insider Buy	William D. Humphries President, Ortho-Dermatologics	$21.18 CAGR »	$650,142.17 30,703 shares
2-28-2019 Insider Buy	Joseph C. Papa CHAIRMAN & CEO	$23.67 CAGR »	$710,100.00 30,000 shares
12-14-2018 Insider Buy	Thomas Appio Pres&Co-Head Bausch&Lomb/Int'l	$22.96 CAGR »	$584,018.45 25,440 shares
9-14-2018 Insider Buy	Joseph C. Papa CHAIRMAN & CEO	$22.32 CAGR »	$669,600.00 30,000 shares
9-14-2018 Insider Buy	Paul Herendeen EVP and CFO	$22.61 CAGR »	$226,100.00 10,000 shares
9-13-2018 Insider Buy	Richard U. De Schutter Director	$23.96 CAGR »	$2,995,000.00 125,000 shares

Also See: Institutional Holders of BHC
Also See: SEC filings

Below we present the annualized performance delivered by Bausch Health Companies stock since 11-30-2021 (the date of the most recent insider purchase). The performance of the investment from the time Bausch Health Companies insider buying occurred is the ultimate test of whether insiders were right about BHC being a good buy.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	12/01/2021
End date:	04/18/2024
Start price/share:	$23.00
End price/share:	$8.60
Dividends collected/share:	$0.00
Total return:	-62.61%
Average Annual Total Return:	-33.88%
Starting investment:	$10,000.00
Ending investment:	$3,738.84
Years:	2.38

Bausch Health Companies Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Bausch Health Companies insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding BHC

BHC — Current Quote

Quotes delayed 20 minutes

Free BHC Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

BHC — Performance

Bausch Health Companies Insider Buying

Bausch Health Companies Insider Buying | www.HoldingsChannel.com